Summit Therapeutics (MEX:SMMT) Tariff Resilience Score: 9/10 (As of Sep. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:SMMT Summit Therapeutics Inc MEX:SMMT
30 GF Score
Price MXN290.12
! 2 Warning Signs
View Full Analysis

What is Summit Therapeutics Tariff Resilience Score?

Summit Therapeutics MEX:SMMT 30 Tariff Resilience Score is 9 as of Sep. 09, 2026. GuruFocus rates MEX:SMMT with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 1,358 Biotechnology companies, Summit Therapeutics ranks better than 99.93% on this metric.

Summit Therapeutics has the Tariff Resilience Score of 9, which implies that the company might have Highly Resilient.

Summit Therapeutics has Summit Therapeutics is highly resilient to tariffs due to its focus on pharmaceuticals, which are often exempt from tariffs. The company has minimal direct import/export activities and operates primarily in regulated markets with stable trade policies.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Summit Therapeutics might have Highly Resilient.

Summit Therapeutics  (MEX:SMMT) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Summit Therapeutics Tariff Resilience Score Related Terms

MEX:SMMT vs TECH, AXSM, KRYS: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Summit Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Summit Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Summit Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Summit Therapeutics's Tariff Resilience Score falls into.


MEX:SMMT
30GF Score
Summit Therapeutics Inc MEX:SMMT
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 9 mean?
Summit Therapeutics (MEX:SMMT) has a Tariff Resilience Score of 9 as of Sep. 09, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Summit Therapeutics ranks #1 out of 1358 companies in the Biotechnology industry, placing it in the top 0.099999999999994%.
Is Summit Therapeutics' Tariff Resilience Score too high?
Summit Therapeutics' current Tariff Resilience Score is 9. The Biotechnology industry median Tariff Resilience Score is 4.00. Summit Therapeutics' value of 9 is 125% above this industry median. Based on the distribution chart, Summit Therapeutics ranks #1 out of 1358 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Summit Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Summit Therapeutics' Tariff Resilience Score compare to TECH and AXSM?
According to the Biotechnology industry distribution chart, Summit Therapeutics ranks #1 out of 1358 companies for Tariff Resilience Score. This places Summit Therapeutics in the top 0% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Summit Therapeutics' value of 9 is 125% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,358 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Summit Therapeutics's current Tariff Resilience Score of 9 is 125% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Summit Therapeutics's current Tariff Resilience Score is 9. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Summit Therapeutics stock overvalued right now?
Summit Therapeutics (MEX:SMMT) has a current Tariff Resilience Score of 9. The current Tariff Resilience Score is 9 and 125% above the Biotechnology industry median of 4.00. Summit Therapeutics' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Summit Therapeutics (MEX:SMMT), the current Tariff Resilience Score is 9 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Summit Therapeutics Business Description

Other Exchanges SMMT:USA
Address 601 Brickell Key Drive, Suite 1000, Miami, FL, USA, 33131
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
30GF Score

Get the complete analysis for MEX:SMMT

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN290.12
Price